Arcturus Therapeutics (ARCT) shares soared 8.7% in the last trading session to close at $19.62. The move was backed by solid volume with far more shares changing hands than in a normal session. This ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arcturus Therapeutics ( (ARCT)) has ...

Arcturus Therapeutics Holdings Inc’s stock price closed at $11.40. It is down -2.06% in the last 3 months and down -42.04% in the last 12 months. Arcturus Therapeutics Holdings Inc saw 0 positive EPS ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company specializing in mRNA therapeutics and vaccines, stands at a critical juncture as it navigates a rapidly ...

During the last three months, 7 analysts shared their evaluations of Arcturus Therapeutics ARCT, revealing diverse outlooks from bullish to bearish. The following table summarizes their recent ratings ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) missed earnings with its latest annual results, disappointing overly-optimistic forecasters. Unfortunately, Arcturus Therapeutics Holdings delivered a ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating success ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...

Lying at the L5 Lagrangian point of Themis are the fused metal fragments of Arcturus Station, destroyed by Reaper capital ships. Arcturus Station was the gateway to Sol, a 5-kilometer diameter ...

** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** Gun socks are a great, inexpensive ...

The Phase 1b trial showed improvements in FEV1 in the four adults with cystic fibrosis after two inhaled administrations. No bronchospasm or febrile reactions were observed. Get access to the ...

Shares of Arcturus Therapeutics Holdings Inc. ARCT have surged 73% in the past three months compared with the industry’s growth of 10.5%. Last month, the European Commission granted orphan medicinal ...